HAYWARD, Calif., March 12, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond ...

Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.

Pulse Biosciences, Inc. , developer of the novel nPulsetm technology using its proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) energy, today announced first patient ...

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 10:30 AM EDTCompany ParticipantsThierry Pieton - Executive VP ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...

Pulse Biosciences, Inc. , developer of the novel nPulsetm technology using proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) energy, today announced clinical data on outcomes ...

Stereotaxis (NYSE:STXS) today reported its fourth-quarter and full-year financial results ahead of expected growth in 2026.

Two such companies in the healthcare sector are Bristol Myers Squibb (NYSE: BMY) and Medtronic (NYSE: MDT). In addition to ...

HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.

Kyle Bauser, ROTH Capital Partners, LLC, Research Division: Asked about 2026 revenue mix and initial MAGiC feedback. Fischel reported most revenue growth will come from disposables as manufacturing ...

A new treatment for irregular heartbeats, pulsed field ablation, or PFA, reduces patient burden and offers high success rates. We also explore a food component that may help prevent the condition.